$108.78
Jazz Pharmaceuticals is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Jazz Pharmaceuticals employs 2,800 staff and has a trailing 12-month revenue of around $3.8 billion.
Our top picks for where to buy Jazz Pharmaceuticals stock
How to buy Jazz Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – JAZZ. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Jazz Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Jazz Pharmaceuticals stock price (NASDAQ: JAZZ)
Use our graph to track the performance of JAZZ stocks over time.Jazz Pharmaceuticals shares at a glance
Latest market close | $108.44 |
---|---|
52-week range | $99.06 - $146.70 |
50-day moving average | $107.34 |
200-day moving average | $117.48 |
Wall St. target price | $178.56 |
PE ratio | 22.5694 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $4.83 |
Is it a good time to buy Jazz Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Jazz Pharmaceuticals price performance over time
Historical closes compared with the close of $108.44 from 2024-07-23
1 week (2024-07-18) | -0.37% |
---|---|
1 month (2024-06-25) | 0.33% |
3 months (2024-04-25) | 0.94% |
6 months (2024-01-25) | -11.71% |
1 year (2023-07-25) | -17.74% |
---|---|
2 years (2022-07-25) | -31.22% |
3 years (2021-07-23) | 173.93 |
5 years (2019-07-25) | 136 |
Is Jazz Pharmaceuticals stock undervalued or overvalued?
Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jazz Pharmaceuticals's P/E ratio
Jazz Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Jazz Pharmaceuticals shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Jazz Pharmaceuticals's PEG ratio
Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8357. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Jazz Pharmaceuticals's EBITDA
Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 billion.
The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Jazz Pharmaceuticals financials
Revenue TTM | $3.8 billion |
---|---|
Operating margin TTM | 11.66% |
Gross profit TTM | $3.4 billion |
Return on assets TTM | 4.07% |
Return on equity TTM | 9.41% |
Profit margin | 8.61% |
Book value | $58.65 |
Market Capitalization | $6.9 billion |
TTM: trailing 12 months
Jazz Pharmaceuticals share dividends
We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.
Jazz Pharmaceuticals share price volatility
Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $99.06 up to $146.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.583. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).
Jazz Pharmaceuticals overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. .
Frequently asked questions
What percentage of Jazz Pharmaceuticals is owned by insiders or institutions?Currently 2.778% of Jazz Pharmaceuticals shares are held by insiders and 96.309% by institutions. How many people work for Jazz Pharmaceuticals?
Latest data suggests 2,800 work at Jazz Pharmaceuticals. When does the fiscal year end for Jazz Pharmaceuticals?
Jazz Pharmaceuticals's fiscal year ends in December. Where is Jazz Pharmaceuticals based?
Jazz Pharmaceuticals's address is: Waterloo Exchange, Dublin, Ireland, D04 E5W7 What is Jazz Pharmaceuticals's ISIN number?
Jazz Pharmaceuticals's international securities identification number is: USG508711052 What is Jazz Pharmaceuticals's CUSIP number?
Jazz Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 472147107
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question